Melatonin alleviates cyclophosphamide-induced ovarian toxicity in mice
Authors:
- Gonzalo OubiñaGOGonzalo Oubiña
- María MayMMMaría May
- María Silvia BianchiMBMaría Silvia Bianchi
- Melanie NeiraMNMelanie Neira
- Eugenia MatzkinEMEugenia Matzkin
- Mónica FrungieriMFMónica Frungieri
- Natalia PascualiNPNatalia Pascuali
- Mayra BordaquievichMBMayra Bordaquievich
- Dalhia AbramovichDADalhia Abramovich
- Fernanda ParborellFPFernanda Parborell
- 16 September 2025
- journal article
- fertility preservation
- Published by Springer Nature in Journal of Assisted Reproduction and Genetics
- Vol. 42 (11) , 3695-3712
Abstract
Purpose Anticancer drugs like cyclophosphamide (CTX) cause severe ovarian damage, often leading to infertility, while current fertility preservation methods are invasive and costly. This study investigates whether melatonin (MEL) can protect ovarian function in a CTX-induced premature ovarian failure (POF) mouse model, offering a potential noninvasive and cost-effective fertoprotective approach. Methods A CTX-induced POF mouse model was used to assess MEL’s protective effects. Ovarian function was evaluated by analyzing follicle counts, ovarian weight, serum hormone levels, apoptosis markers, histopathological changes, vascular integrity, and antioxidant defences. Results MEL coadministration increased the proportion of primary and antral follicles (p < 0.01 and p < 0.05) while reducing atretic follicles (p < 0.05). MEL preserved ovarian weight, maintained primordial follicle counts, and prevented CTX-induced hormone level reductions. MEL also enhanced AMH-positive follicle percentage, reduced apoptosis, and mitigated vascular injury, fibrosis, and blood vessel hyalinization (p < 0.05). Furthermore, MEL restored uterine tissue architecture, improved vascular health by recruiting pericytes and smooth muscle cells (p < 0.05), and enhanced antioxidant defenses through increased expression of superoxide dismutase 1 (SOD1) (p < 0.05). Conclusion MEL effectively preserves ovarian function in a CTX-induced POF model by protecting follicular development, hormonal balance, vascular integrity, and antioxidant defenses. These findings highlight MEL as a promising, noninvasive, and cost-effective strategy for fertility preservation in female cancer patients undergoing chemotherapy.Keywords
Funding Information
- Cancer national institute (INC 2020-2022)
- ANPCyT (1603-2017)
This publication has 84 references indexed in Scilit:
- Resveratrol alleviates doxorubicin-induced damage in mice ovaryChemico-Biological Interactions, 2023
- Crucial role of high-mobility group box 2 in mouse ovarian follicular development through estrogen receptor betaHistochemistry and Cell Biology, 2022
- The protective effect of platelet-rich plasma administrated on ovarian function in female rats with Cy-induced ovarian damageJournal of Assisted Reproduction and Genetics, 2020
- Intrafollicular melatonin concentration is elevated in patients with ovarian hyperstimulation syndrome (OHSS) and can serve as an important predictor of OHSSArchives of Gynecology and Obstetrics, 2019
- Evidence of melatonin synthesis in the cumulus oocyte complexes and its role in enhancing oocyte maturation in vitro in cattleMolecular Reproduction and Development, 2011
- Normal ovarian function and assessment of ovarian reserve in the survivor of childhood cancerPediatric Blood & Cancer, 2009
- Regulation of follicular luteinization by a gonadotropin-releasing hormone agonist: Relationship between steroidogenesis and apoptosisMolecular Reproduction and Development, 1998
- Reproductive toxicity of cyclophosphamide in the C57BL/6N mouse: 2. Effects on uterine structure and functionReproductive Toxicology, 1992
- The effect of cyclophosphamide on mouse oocyte in vitro fertilization and cleavage: RecoveryReproductive Toxicology, 1991
- Effect of “activated” cyclophosphamide on mouse oocyte in vitro fertilization and cleavageReproductive Toxicology, 1988